Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases
Grant
Overview
Affiliation
Overview
Awarded By
University of North Carolina at Chapel Hill
Total Award Amount
43500.00
Direct Costs
34524.00
Sponsor Award Id
Affiliation
Contributor
Lisle Nabell M.D.
Principal Investigator